Cohort B, including 84 patients who were PD-L1 positive on tumor cells or in the stroma and who had no prior metastatic treatment, experienced a higher ORR of 23.1%, and the median DOR was 8.4 months. This evidence concerns the gene CD274 and neoplasm.